Vaxcyte, Inc.

This study tests a new vaccine called VAX-31 to prevent pneumococcal disease (like pneumonia) in healthy adults aged 50 and older, and also checks if it works similarly in younger adults aged 18-49. About 4,000 participants will receive either VAX-31 or an existing vaccine to com…

This study tests a new vaccine called VAX-31 in 752 healthy adults aged 50 and older who have already received a pneumonia vaccine. The goal is to see if VAX-31 is safe and triggers a strong immune response. Participants receive either VAX-31 or an existing vaccine, and researche…

This study tests a new vaccine called VAX-31 in healthy infants to see if it safely protects against pneumococcal infections better than the current vaccine. Around 900 babies will receive four doses at 2, 4, 6, and 12-15 months old, alongside their routine shots. Researchers wil…

This study tests a new vaccine called VAX-31, which targets 31 types of bacteria that cause pneumonia and other infections. Researchers want to see if it is safe and works well when given at the same time as the seasonal flu shot in healthy adults aged 50 and older. About 1,390 p…